Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HARRIS & HARRIS GROUP INC /NY/v304983_ex99-1.htm
EX-99.2 - EXHIBIT 99.2 - HARRIS & HARRIS GROUP INC /NY/v304983_ex99-2.htm

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

                               

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

 

March 7, 2012 (March 7, 2012)

                              

 

HARRIS & HARRIS GROUP, INC.

 

(Exact name of registrant as specified in its charter)

         
New York
(State or other jurisdiction of
incorporation)
  0-11576
(Commission File
Number)
  13-3119827
(IRS Employer
Identification No.)

                               

1450 Broadway
New York, New York 10018

 

(Address of principal executive offices and zip code)

(212) 582-0900

 

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  

Item 8.01. Other Events.

 

Harris & Harris Group, Inc. (the “Company”) noted the announcement that its portfolio company, Mersana Therapeutics, Inc., entered into a collaboration agreement with Endo Pharmaceutical (NASDAQ: ENDP) to develop next-generation antibody-drug conjugates (ADCs).

 

The Company also today announced its $815,000 investment in privately-held OpGen, Inc.

 

The Company's press releases are attached hereto as Exhibit 99.1 and 99.2.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Not applicable.

 

(b)    Not applicable.

 

(c)     Not applicable.

 

(d)    Exhibits.

 

Exhibit No. Description

 

99.1Mersana Press Release dated March 7, 2012

 

99.2OpGen Press Release dated March 7, 2012

 

2
 

  

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Date: March 7, 2012 HARRIS & HARRIS GROUP, INC.
   
  By:  /s/ Douglas W. Jamison
    Douglas W. Jamison
Chairman and Chief Executive Officer

 

3
 

 

EXHIBIT INDEX

 

 

Exhibit No. Description

 

99.1 Mersana Press Release dated March 7, 2012

 

99.2 OpGen Press Release dated March 7, 2012